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Abstract
 
Induction of proinflammatory cytokine responses by glycosylphosphatidylinositols (GPIs) of in-
traerythrocytic 
 
Plasmodium falciparum
 
 is believed to contribute to malaria pathogenesis. In this
study, we purified the GPIs of 
 
P. falciparum
 
 to homogeneity and determined their structures by
biochemical degradations and mass spectrometry. The parasite GPIs differ from those of the
host in that they contain palmitic (major) and myristic (minor) acids at C-2 of inositol, pre-
dominantly C18:0 and C18:1 at 
 
sn-
 
1 and 
 
sn
 
-2, respectively, and do not contain additional
phosphoethanolamine substitution in their core glycan structures. The purified parasite GPIs
can induce tumor necrosis factor 
 
a
 
 release from macrophages. We also report a new finding
that adults who have resistance to clinical malaria contain high levels of persistent anti-GPI an-
tibodies, whereas susceptible children lack or have low levels of short-lived antibody response.
Individuals who were not exposed to the malaria parasite completely lack anti-GPI antibodies.
Absence of a persistent anti-GPI antibody response correlated with malaria-specific anemia and
fever, suggesting that anti-GPI antibodies provide protection against clinical malaria. The anti-
bodies are mainly directed against the acylated phosphoinositol portion of GPIs. These results
are likely to be valuable in studies aimed at the evaluation of chemically defined structures for
toxicity versus immunogenicity with implications for the development of GPI-based therapies
or vaccines.
Key words: malaria parasite • cytokine response • antigenicity • acquired immunity • 
pathogenesis
 
Introduction
 
The rapid spread of drug-resistant 
 
Plasmodium falciparum
 
and the lack of an effective malaria vaccine present an ur-
gent need for alternative approaches to prevent malaria in-
fection and pathogenesis (1). It is becoming increasingly
clear that complete protection against malaria infection and
illness requires multifactorial immunity (2). Currently,
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most vaccine efforts are aimed at immunity against infec-
tion (antiparasitic) by targeting the parasite proteins (2–5).
However, it has long been suggested that immunity against
severe malaria is partly antiparasitic and partly antitoxic
(toxic effects in response to parasite factors). The majority
of the adults in malaria endemic areas have resistance to se-
vere malaria. However, most children 
 
,
 
4 yr of age are sus-
ceptible despite exposure to high malaria transmission,
which can produce high levels of antibodies against protein
antigens including merozoite surface protein (MSP)
 
1
 
-1,
erythrocyte membrane antigen
 
 
 
(EBA)-175, and apical
membrane antigen 1 (AMA)-1. Although antibody re-
sponses against parasite proteins correlate with protection
against parasitemia (Branch, O.H., unpublished results), re-
sistance to malaria illness is independent of parasitemia lev-
els. This agrees with the resistance of adults and older chil-
dren to malaria pathology even though they can develop
significant parasitemia (6); conversely, severe illness can oc-
cur at relatively low-density parasitemias independent of
antibody response against parasite proteins (7–9). The fac-
tors associated with the resistance to clinical disease (anti-
disease immunity) have not been established; understanding
these would lead to alternative approaches for malaria con-
trol. In this regard, parasite glycosylphosphatidylinositols
(GPIs) appear to offer new opportunities.
GPIs are a distinct class of glycolipids found ubiquitously
in eukaryotic cells and implicated in several biological re-
sponses (10–12). GPIs are particularly abundant in parasites,
where they are found as free lipids and attached to proteins.
In intraerythrocytic 
 
P. falciparum
 
, GPIs represent the major
glycoconjugates. Several functionally important parasite
proteins, including MSP-1, MSP-2, and MSP-4, are an-
chored to the cell membranes through GPI moieties (13–
17). Recently, we have shown that 
 
P. falciparum
 
 synthesizes
GPIs in a developmental stage–specific manner and that
GPI biosynthesis is crucial for the development and survival
of the parasite (18). The enzyme specificity of some key
steps of parasite GPI biosynthesis differs significantly from
those of the host, suggesting the possibility of targeting the
parasite GPI structures for the development of antiparasitic
drugs. However, detailed structures of parasite GPIs have
not been determined. Although the structures of glycan
cores have been established using metabolically labeled
GPIs (19, 20), details regarding the nature of various acyl
residues and other possible substitutents were not clear
(21). Determination of a detailed structure requires isola-
tion of pure GPIs which, in the case of 
 
P. falciparum
 
, is a
challenge due to the difficulty in obtaining adequate
amounts of parasites free of host cell components. In this
study, we were able to successfully purify 
 
P. falciparum
 
 GPIs
to homogeneity and establish their structures.
 
It has long been believed that malaria pathology is due to
factors endogenously produced in response to parasite tox-
ins. Several studies have shown that malaria pathology is at
least in part due to parasite toxic factors that can induce
TNF-
 
a
 
 and other cytokines, which could then lead to
clinical effects including fever, hypoglycemia, dyserythro-
poiesis, and vascular damage in the lungs and brain (22, 23).
This agrees with the elevated levels of TNF-
 
a
 
 in patients
with lethal cerebral malaria (24) and the ability of anti–
TNF-
 
a
 
 antibodies to prevent lethal cerebral pathology in
mice (25).
 
P. falciparum
 
 GPIs have been identified as malaria patho-
genicity factors based on their ability to induce inflamma-
tory cytokines in macrophages and endothelial cells and
cause symptoms reminiscent of acute malaria infection in
experimental animals (26–29). Schofield et al. (26) have
shown that parasite fractions enriched with GPIs can in-
duce TNF-
 
a
 
 and IL-1 in macrophages; in mice, GPIs can
cause transient pyrexia, hypoglycemia, lethal cachexia, and
even death in 
 
D
 
-galactosamine (GalN)-sensitized animals.
Schofield et al. have also shown that 
 
P. falciparum
 
 GPIs ex-
ert toxic effects through the expression of TNF-
 
a
 
, IL-1,
inducible nitric oxide synthase (iNOS), and endothelial cell
adhesion molecules by activating nuclear factor 
 
k
 
B tran-
scription factors (27–29). As 
 
P. falciparum
 
–infected erythro-
cytes are sequestered in specific organs, the local high con-
centrations of toxic responses to the parasite GPIs can affect
vital physiologic functions and cause severe illness. Recent
studies have shown that GPIs from a 
 
Trypanosoma cruzi
 
 mu-
cin can also induce proinflammatory cytokines (30). The
antagonists of GPI-mediated signaling and a monoclonal
antibody against 
 
P. falciparum
 
 GPIs can block the induction
of toxic responses (27–29), suggesting that GPI-based ther-
apy is possible.
Because 
 
P. falciparum
 
 GPIs are pathogenicity factors, we
hypothesized that adults in malaria endemic areas should
have GPI-specific protective immunity. We tested this hy-
pothesis by analyzing the anti-GPI antibody response in
sera from a longitudinal cohort study and in sera of a large
group of adults from Western Kenya. The data demon-
strate for the first time that people living in malaria en-
demic areas elicit a parasite GPI–specific IgG response in an
age-dependent manner; although adults and older children
have high levels of antibodies, malaria-susceptible children
either lack or have only very low levels of short-lived anti-
bodies. The results also suggest the involvement of anti-
GPI antibodies in protection against malaria pathogenesis.
 
Materials and Methods
 
Reagents.
 
Human blood and serum were purchased from In-
terstate Blood Bank. RPMI 1640, DME, and cell culture reagents
were from Life Technologies. Gelatin, bee venom phospholipase
A
 
2
 
 (1,800 U/mg), standard phospholipids, and saponin were from
Sigma-Aldrich. Silica Gel 60 high performance thin-layer chro-
matography (HPTLC) plates were from either EM Science or
Whatman. Pronase was purchased from Calbiochem. 
 
Aspergillus
saitoi 
 
a
 
-mannosidase (400 mU/mg) and jack bean 
 
a
 
-mannosidase
 
1
 
Abbreviations used in this paper:
 
 AHM, 2,5-anhydromannitol; CL, cardio-
lipin; EBA, erythrocyte membrane antigen; GalN, galactosamine; GC-
MS, gas chromatography–mass spectrometry; GlcN, glucosamine; GPI,
glycosylphosphatidylinositol; HF, hydrofluoric acid; HPTLC, high per-
formance thin-layer chromatography; HRP, horseradish peroxidase;
MSP, merozoite surface protein; PG, phosphoglyceride; PI, phosphati-
dylinositol. 
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(30 U/mg) were from Oxford Glycosystems. Poly(isobutyl meth-
acrylate) was procured from Polysciences, Inc. Horseradish per-
oxidase (HRP)-conjugated goat anti–human IgG (H and L
chains) and 2,2
 
9
 
-azino-bis(3-ethylbenz-thiazoline-6-sulfonic acid)
(ABTS) reagent were from Kirkegaard & Perry Laboratories.
Microtiter plates were from Dynex Technologies. [6-
 
3
 
H]glu-
cosamine (GlcN; 23 Ci/mmol), and [
 
3
 
H]arachidonic (202 Ci/
mmol), [
 
3
 
H]myristic (55 Ci/mmol), and [
 
3
 
H]oleic acids (8 Ci/
mmol) were from Amersham Pharmacia Biotech. [
 
3
 
H]Linoleic
(60 Ci/mmol), [
 
3
 
H]palmitic (60 Ci/mmol), [
 
3
 
H]palmitoleic (60
Ci/mmol), and [
 
3
 
H]stearic acids (60 Ci/mmol) were from Amer-
ican Radiolabeled Chemicals. 
 
125
 
I-labeled goat anti–human IgG
(8.66 
 
m
 
Ci/
 
m
 
g) and En
 
3
 
Hance were from NEN Life Science
Products. Murine macrophages (J774A.1) were from American
Type Culture Collection. HPLC grade solvents were used
throughout the study.
 
Cell Culture and Isolation of Parasites.
 
Intraerythrocytic 
 
P. falci-
parum
 
 (FCR-3 strain) was cultured in RPMI 1640 using human
O-type erythrocytes and 10% O-positive human serum at 3–4%
hematocrit (18, 19). Cultures were routinely synchronized with
5% sorbitol (31) and tested for mycoplasma (32); only contamina-
tion-free cultures were used.
Cultures with 20–30% parasitemia were harvested at mid-
schizont stage. Packed erythrocytes (20 ml) suspended in 180 ml
of 0.65% gelatin in culture medium were incubated at 37
 
8
 
C for
30 min (33). The enriched infected erythrocytes (70–80% para-
sitemia) in the supernatant were recovered and lysed with 0.015%
saponin in Trager’s buffer (34). The suspension was passed
through a 26-gauge needle to solubilize the erythrocyte debris
and then centrifuged. The parasites were suspended in the above
buffer, layered on 5% BSA, and centrifuged (35). The packed
parasites (
 
z
 
4 ml) were washed with the buffer and stored at
 
2
 
80
 
8
 
C until used.
 
Metabolic Labeling of the GPIs.
 
Parasites were radiolabeled in
medium containing 5 mM glucose and [
 
3
 
H]GlcN (50 
 
m
 
Ci/ml;
reference 19). Labeling with 
 
3
 
H–fatty acids (50 
 
m
 
Ci/ml) was per-
formed in medium containing 2% serum and 20 mM glucose.
 
Isolation of GPIs.
 
All procedures were carried out using acid-
washed, siliconized glassware to prevent surface adsorption of
GPIs, high quality solvents, and sterile water and buffers. Parasites
(10 ml) were lyophilized and extracted three times with 50 ml of
chloroform/methanol (2:1, vol/vol) to remove nonglycosylated
lipids. The pellet was extracted five times with 50 ml of CMW
(chloroform/methanol/water, 10:10:3 [vol/vol/vol]), dried, and
then partitioned between water and water-saturated 1-butanol.
The organic layer was dried and the residue was extracted with
80% aqueous 1-propanol. Finally, GPIs were purified by HPLC
and HPTLC.
To isolate GPIs that are linked to parasite proteins, the delipi-
dated parasite pellet was digested with pronase (50 U/ml) in 50
ml of 100 mM NH
 
4
 
HCO
 
3
 
, 1 mM CaCl
 
2
 
, pH 8.0, at 37
 
8
 
C for
24 h. The released GPIs (designated as amino acid–linked GPIs)
were extracted with water-saturated 1-butanol, washed with wa-
ter, dried, and purified by HPLC. Control erythrocyte membrane
debris, saponin-lysate, and ghosts were similarly extracted and
fractionated.
 
HPLC Purification of GPIs.
 
The GPIs (
 
z
 
10 
 
m
 
g plus 400,000
cpm of [
 
3
 
H]GlcN-labeled GPIs) were chromatographed on a C
 
4
 
reversed phase Supelcosil LC-304 HPLC column (4.6 
 
3
 
 250
mm, 5 
 
m
 
m particle size; Supelco) using a linear gradient of 20–
60% aqueous 1-propanol containing 0.1% TFA over a period of
80 min and held for 30 min at a flow rate of 0.5 ml/min (36).
Fractions (1.0 ml) were collected, and elution of GPIs was moni-
 
tored by measuring radioactivity. Aliquots (0.5 
 
m
 
l) were also as-
sayed by ELISA with Kenyan adult sera. Glycolipids extracted
from control erythrocyte membrane debris, total lysate, and
ghosts were similarly chromatographed, and fractions were ana-
lyzed for reactivity with Kenyan sera.
 
Purification and Analysis of GPIs by HPTLC.
 
The HPLC-puri-
fied GPIs (5 
 
m
 
g) were applied onto 10 
 
3
 
 10–cm plates as con-
tinuous streaks. Parallel spots with [
 
3
 
H]GlcN-labeled GPIs
(50,000 cpm) were used for monitoring GPI bands by fluorogra-
phy using En
 
3
 
Hance (18, 19). The plates were developed with
CMW (10:10:2.5, vol/vol/vol). GPIs from the plates were ex-
tracted with CMW (10:10:3, vol/vol/vol), dried, dissolved in
water-saturated 1-butanol, and washed with water.
In separate experiments, HPTLC plates were scraped (0.5-cm-
width fractions), and GPIs were extracted and analyzed by ELISA
using Kenyan adult sera. Glycolipids from control erythrocyte
membrane debris, total lysate, and ghosts were similarly analyzed.
 
Compositional Analysis.
 
HPLC- and HPTLC-purified, free
and amino acid–linked GPIs (4–5 
 
m
 
g each), and hydrofluoric acid
(HF)-released inositol-acylated carbohydrate moiety (2–3 
 
m
 
g),
and diacylglycerol moiety (1–2 
 
m
 
g) were treated with 8 M anhy-
drous methanolic KOH for 2 h at 120
 
8
 
C. After acidification with
cold dilute HCl, the fatty acid methyl esters were extracted with
chloroform. Phospholipase A
 
2
 
–released fatty acids were esterified
with methyl iodide in DMSO/solid NaOH. Gas chromatogra-
phy–mass spectrometry (GC-MS) was performed on a Thermo-
Quest GCQ
 
plus
 
 ion trap electron ionization quadrupole mass
spectrometer (Finnigan) using DB-5 capillary column (30 m 
 
3
 
0.25 mm interior diameter with 0.25-
 
m
 
m film; Alltech). The
temperature was held at 75
 
8
 
C for 1 min, raised to 150
 
8
 
C at 1
 
8
 
C/
min, and then to 325
 
8
 
C at 8
 
8
 
C/min. GC retention times and
mass spectra were compared against standards.
The free and amino acid–linked GPIs (
 
z
 
2 
 
m
 
g each) were hy-
drolyzed with 2.5 M TFA at 100
 
8
 
C for 5 h, and the hydrolysates
were analyzed for mannose by HPLC (37).
 
Mass Spectrometry.
 
Matrix-assisted laser-desorption/ioniza-
tion time of flight mass spectrometry analysis was performed using
a Kratos analytical MALDI-4 mass spectrometer equipped with a
nitrogen laser at 20-kV accelerating voltage (38). Spectra were ac-
quired with a time-delayed extraction and were the average of 50
laser shots. The matrix was saturated with 
 
a
 
-cyano-4-hydroxy-
cinnamic acid in 50% ethanol. The mass accuracy was within 2
daltons.
TNF-a Induction by GPIs. Murine macrophages (1.5 3 106
cells/well in 96-well plates) in DMEM and 10% fetal bovine se-
rum were stimulated with 0.03–0.5 mM HPTLC-purified, free
and amino acid–linked GPIs (see Fig. 1 B, lanes 2 and 4, respec-
tively). TNF-a in the culture supernatants was measured by a
quantitative sandwich ELISA using the TNF-a estimation kit
(R&D Systems). Experiments were performed in triplicate with
three separate batches of GPI preparations.
IgG-specific ELISA. HPLC-purified, free GPIs dissolved in
methanol were coated (0.25–32 ng/well) onto 96-well microtiter
plates. After evaporation of methanol at 378C, the wells were
blocked with 0.5% casein in 50 mM Tris-buffered saline, pH 7.4
(TBS-casein), and incubated with serially diluted sera (1:100 to
1:64,000) in TBS-casein containing 0.05% Tween 20. Initially,
randomly selected 20 Kenyan and 2 USA adult sera were assayed.
The bound antibodies were measured by HRP-conjugated goat
anti–human IgG and ABTS substrate. All other sera were ana-
lyzed at 1:200 or 1:400 dilution by coating GPIs at 0.5–2 ng/well.
Competitive Inhibition ELISA. Sera were diluted 1:200 in
TBS-casein containing 0.05% Tween 20 and incubated at room1566 Structure and Antibody Response of P. falciparum GPIs
temperature for 30 min with various concentrations of phosphati-
dylinositols (PIs), phosphoglyceride (PG), cardiolipin (CL), or
GPI, and then ELISA was performed as described above.
TLC Immunoblotting. The HPLC-purified, free and amino
acid–linked GPIs (100 ng each) were chromatographed on
HPTLC plates. The plates were soaked in 0.1% poly(isobutyl
methacrylate) in hexane, dried, and incubated for 2 h at room
temperature with TBS containing 1% BSA and then for 2 h in
1:100 diluted sera (39). The plates were washed with cold phos-
phate-buffered saline, incubated with 125I-labeled goat anti–
human IgG (5 mCi/ml) for 1 h, washed, dried, and exposed to
x-ray film.
Nitrous Acid Treatment. The HPLC-purified, free GPIs (20
mg) suspended in 150 ml 0.2 M NaOAc, pH 3.8, were treated
with 150 ml 1 M NaNO2 at room temperature for 24 h (40). The
released PI moieties were extracted with water-saturated 1-buta-
nol. The glycan moieties were recovered by chromatography on
a Bio-Gel P-4 column (1 3 90 cm) in 100 mM pyridine, 100
mM HOAc, pH 5.2. These were used to assess seroreactivity.
Treatment with HF. The HPLC-purified, free GPIs (2 mg plus
500,000 cpm of [3H]GlcN-labeled GPIs) were treated with 50%
aqueous HF (50 ml) in an ice bath for 48 h (40). The reaction
mixture was neutralized with LiOH and extracted with water-
saturated 1-butanol. The organic layer was washed with water,
dried, and the carbohydrate moiety was purified by HPLC.
Treatment with Mannosidase. The [3H]GlcN-labeled GPI gly-
can cores (10,000 cpm) were digested with jack bean a-mannosi-
dase and the products were deionized with AG 50W-X16 (H1)
and lyophilized (19). The glycan cores (5,000 cpm) were digested
with A. saitoi a-mannosidase (0.5 mU/ml), deionized, and ly-
ophilized (19).
Treatment with Phospholipase A2. HPLC-purified GPIs (2 mg)
in 100 ml 100 mM Tris-HCl, 10 mM CaCl2, pH 7.5, were
treated with bee venom phospholipase A2 (2,400 U/ml) at 378C
for 18 h. The digest was extracted with water-saturated 1-butanol
and purified by HPLC; the retention time of lyso-GPIs is
75.5  min.
Analysis of Cohort Sera for Anti-GPI Antibodies. Sera were ob-
tained from subjects of a longitudinal malaria project performed
in a holoendemic, rural region of Western Kenya within the con-
text of the Asembo Bay Cohort Project (ABCP [8]). Studies done
in the subjects’ households show that from March to May the en-
tomological inoculation rate (EIR) was z30 infected bites per
person per month, whereas during the drier months the EIR was
z4. Pregnant mothers were identified and, after written consent,
they, their delivered infants, and older children living in the same
household were enrolled. The mothers and children were fol-
lowed every 2 wk for z4 yr, and clinical parameters, axillary
temperature, and illness were recorded. Blood samples were
taken monthly and parasite and hemoglobin density were mea-
sured. More than 90% of detected parasitemias contained P. falci-
parum species.
Sera of 100 7–8-yr-old children and 50 nonpregnant adults,
collected during February through August 1993, were analyzed at
two time points, spaced 1–3 mo apart. For data analysis, we se-
lected two time points for the young children, in the same man-
ner as the older individuals, when they were z0.5, 1.5, 2.5, and
3.5 yr old. The study was approved by the Centers for Disease
Control and Prevention and Kenyan Institutional Review
Boards.
Analysis of the Relationship between Serum Anti-GPI Antibodies
and Resistance to Malaria Pathogenesis. Analysis for correlation of
anti-GPI antibody response with either hemoglobin or tempera-
ture as the dependent variable was done with the general linear
model, Generalized Estimating Equations (41). The variables
considered in the analyses were (a) anti-GPI antibody responder
category (positive, intermittent, or negative), (b) parasite density,
log10(n 1 1/ml), (c) age, and (d) antimalaria drug treatment. We
controlled for the repeated measures on each patient. The esti-
mated effect of positive and negative antibody responder category
are given relative to that of the intermittent antibody responder
category.
Results
Isolation and Purification of GPIs from Intraerythrocytic P. fal-
ciparum. As contamination with glycolipids from host
erythrocytes and mycoplasma is a major concern in isolat-
ing GPIs from intraerythrocytic P. falciparum, we used rig-
orous protocols. First, parasite cultures were routinely
tested for mycoplasma, and parasite-infected erythrocytes
were enriched from cultures with 25–30 to 70–80% para-
sitemia to minimize erythrocyte components. Second, the
parasites were released from infected erythrocytes by mild
saponin lysis, washed, and purified by density centrifuga-
tion to remove erythrocyte membrane debris; metaboli-
cally [3H]GlcN-labeled cultures revealed that this proce-
dure did not release parasite GPIs. These procedures
eliminated all of the erythrocyte components. Third, the
purified parasites were differentially extracted to remove
most nonglycosylated lipids, and the extract containing the
free GPIs (not linked to proteins) was subjected to solvent
fractionation to eliminate soluble hemozoin and other col-
ored components. Finally, the GPIs were purified by suc-
cessive fractionation using HPLC and HPTLC. The GPIs
that are linked to parasite proteins were isolated after ex-
haustive digestion of the delipidated parasites with pronase,
and are referred to as amino acid–linked GPIs. The yields
of the HPLC-purified free and amino acid–linked GPIs
were 100–120 and 25–30 mg per 10 ml of packed purified
parasites, respectively, based on the mannose content.
The parasite GPIs were purified by HPLC using a C4 re-
versed phase column, which separated matured GPIs from
GPI intermediates (Fig. 1 A). The elution of GPIs was
monitored by radioactivity, which overlapped with the re-
activity of the GPIs to human sera containing anti-GPI an-
tibodies (Fig. 1 A). The compounds isolated from the
extracts of erythrocyte debris, lysates, and ghosts were
fractionated in parallel with the purification of parasite
GPIs by HPLC (Fig. 1 A) and HPTLC and analyzed as
controls. These did not react with Kenyan adult sera (Fig. 1
A), suggesting that the activity is specific to parasite GPIs.
The GPIs were further purified by HPTLC; they mi-
grated as broad major bands and in some instances separated
into two major bands (Fig. 1 B). The heterogeneity of
GPIs is due to the variation in the fatty acid composition of
individual GPIs (see below). The HPTLC-purified GPIs
(Fig. 1 B, lanes 2 and 4) contained mannose and GlcN in
molar ratios of z4:1 and were susceptible to nitrous acid,
HF, and alkali (not shown). Fatty acid compositional analy-
sis of HPLC-purified GPIs showed the presence of myristic1567 Naik et al.
(z4%), palmitic (z33%), stearic (z26%), oleic (z28%),
cis-vaccenic (z2%), linoleic (z3%), arachidic (z2%), and
behenic (z1%) acids, and 1–2% of unidentified acids. The
presence of cis-vaccenic acid in the GPIs agrees with the
ability of P. falciparum to synthesize two isomeric C18:1 ac-
ids (oleic and cis-vaccenic acids [42]).
Structural Analysis of P. falciparum GPIs. The structures
of the purified P. falciparum GPIs were determined by spe-
cific chemical and enzymatic degradation studies using
[3H]GlcN- and 3H–fatty acid-labeled GPIs and by mass
spectrometry.
The [3H]GlcN-labeled GPIs were characterized by sub-
jecting them to various degradative procedures. Treatment
with jack bean a-mannosidase quantitatively converted the
[3H]GlcN-labeled GPIs into species with three mannose
residues, similar to the results recently reported (18), sug-
gesting that the distal fourth mannose residue does not con-
tain any substituent. The [3H]GlcN-labeled GPIs were de-
phosphorylated with HF and then deaminated and reduced
with NaBH4. The neutral glycan core, thus obtained, on
HPTLC migrated as a single band with a mobility relative
to the solvent front (Rf) value identical to previously char-
acterized Man4-2,5-anhydromannitol (AHM) (19). Treat-
ment of the glycan core with A. saitoi a-mannosidase
shifted the Rf value to that of authentic Man2-AHM, and
the product of jack bean a-mannosidase digestion comi-
grated with authentic AHM (not shown; 19). These results
are consistent with the previously established structure of
Mana1-2Mana1-2Mana1-6Mana1-4GlcN for the glycan
core of P. falciparum GPIs (19, 20).
The mass spectrum of the purified, free GPIs (upper half
portion of the HPTLC band in Fig. 1 B, lane 2) contained
prominent molecular ions (M-H)2 at m/z 2,006.3 and
2,034.3 and minor ions at m/z 1,978.3, 2,062.3, and
2,090.3 (Fig. 2 A). The observed difference of 28 mass
units (in some fractions 26 units) between the consecutive
molecular ions suggests that the GPIs contain mixtures of
homologous fatty acids differing by two carbons. The pro-
portions of the GPI species varied considerably depending
on the regions of HPTLC band analyzed (compare Fig. 2,
A and B), suggesting heterogeneity with respect to acyl
substitutents. Mass spectrometry of the control materials
did not show molecular ions comparable to the parasite
GPIs (not shown). These results show that the purified
compounds are GPIs of the parasite, not of erythrocytes.
Treatment of free GPIs with phospholipase A2 resulted
in the marked loss of (M-H)2 ions of intact GPIs and the
appearance of a new set of ions, each 264.5 mass units
lower (Fig. 2 B), indicating that the GPIs contain a C18:1
acyl substituent at the sn-2 position. The spectra of some
GPI fractions treated with phospholipase A2 also contained
significant levels of ions 262.5 mass units lower than the
parent ions, suggesting the presence of GPIs with a C18:2
acid at sn-2. GC-MS analysis of phospholipase A2–released
fatty acids demonstrated the presence of predominantly
oleic acid with minor amounts of cis-vaccenic and linoleic
acids. These data together with the total fatty acid compo-
sition indicate that the parasite GPIs contain mainly oleic
(z85%), cis-vaccenic (z6%), and linoleic (z9%) acids at
sn-2.
As reported previously (21), the GPIs were sensitive to
GPI-specific phospholipase D, but completely resistant to
PI–phospholipase C (data not shown), suggesting the pres-
ence of an acyl substituent on C-2 of inositol. To identify
this substituent, the GPIs were treated with HF and the re-
leased inositol-acylated carbohydrate moiety was purified
by HPLC as a single symmetrical peak with a retention
time of 47 min. Fatty acid compositional analysis indicated
that the HF-released inositol-acylated carbohydrate moiety
contained palmitic acid (z90%) and myritsic acid (z10%).
Positive ion–mode mass spectrum showed (M1Na1) ions
at m/z 1,224.4 and 1,252.7 (Fig. 2 C), which were assigned
to Man4-GlcN-inositol with myristoyl and palmitoyl sub-
stitution, respectively, on inositol. The signals at m/z
Figure 1. HPLC and HPTLC purifica-
tion of P. falciparum GPIs. (A) The parasite
GPIs (10 mg plus 400,000 cpm of
[3H]GlcN-labeled GPIs) were chromato-
graphed on a 4.6 3 250–mm C4 reversed
phase HPLC column with a linear gradient
of 20–60% aqueous 1-propanol (reference
37). (Top) Analysis of parasite GPIs: frac-
tions (1.0 ml) were collected and 3H activity
in 5-ml aliquots was measured (d); 0.5-ml
aliquots assayed by ELISA for immunoreac-
tivity with Kenyan adult sera (s). (Bottom)
Analysis of glycolipids from control erythro-
cyte membrane debris obtained from 4 ml
packed erythrocytes (d), and those of delip-
idated, pronase-digested erythrocyte ghosts
from 2 ml packed erythrocytes (s). 1-ml al-
iquots were assayed for immunoreactivity
with Kenyan sera. Extracts of total erythrocyte lysate were similarly analyzed (not shown). (B) Fluorograms of the [3H]GlcN-labeled GPIs chromato-
graphed on Silica Gel 60 HPTLC plates using CMW (10:10:2.5, vol/vol/vol). Lane 1, total free GPIs before HPLC; lane 2, HPLC-purified matured free
GPIs; lane 3, total free GPIs (different preparation from that in lane 1; obtained by culturing parasites in regular medium after replacing medium with ra-
diolabeled precursor to maximally convert intermediates into matured GPIs); and lane 4, HPLC-purified, amino acid–linked GPIs. Each lane contains
200 ng of GPIs plus 20,000 cpm of [3H]GlcN-labeled GPIs. Note that a small amount of free GPIs that remained with parasite pellet even after exhaus-
tive extraction with organic solvents was copurified with amino acid–linked GPIs (lane 4).1568 Structure and Antibody Response of P. falciparum GPIs
1,228.7 and 1,266.8 represent (M1H1) and (M1K1) ions
of the carbohydrate with palmitoyl substitution. Of several
mass spectra recorded, some (not shown) gave a reasonable
signal at m/z 1,200.4, which was assigned to the (M1H1)
ion of the carbohydrate with myristoyl substitution. A sig-
nificant portion of the HF-released glycan moieties re-
tained a phosphate ester group as indicated by the negative
ion mode spectrum, which showed molecular ions at m/z
1,280.0 and 1,308.1 (Fig. 2 D). The phosphate ester group
that survived HF treatment is likely the one linked to inos-
itol because the adjacent protonated GlcN residue will ren-
der the hydrolysis of the phosphate ester bond to be kineti-
cally slower. These results established that the inositol
residue is substituted with palmitate (z90%) and myristate
Figure 2. Mass spectrometry analysis of P. falciparum GPIs. HPLC- and HPTLC-purified
GPIs were analyzed by matrix-assisted laser desorption/ionization time of flight mass spec-
trometry in negative or positive ion mode. (A) Negative ion mass spectrum of the purified free
GPIs (Fig. 1 B, lane 2). (B) Negative ion mass spectrum of phospholipase A2–treated free GPIs
showing (M-H)2 ions of unconverted GPIs and GPIs lacking substituent at sn-2 position. (C)
Positive ion mass spectrum of inositol-acylated glycan moiety released by HF treatment of
GPIs. (D) Negative ion mass spectrum of inositol-acylated glycan moiety released by HF treatment of GPIs. (E) Negative ion mode mass spectrum of the
amino acid–linked GPI fraction I (Fig. 1 B, lane 4). The mass spectrum of fraction II (Fig. 1 B, lane 4) contained (M-H)2 ions at m/z 2147.3 at signifi-
cantly higher proportions compared with fraction I, in addition to an ion at m/z 2175.3 (not shown). (F) Negative ion mass spectrum of phospholipase
A2–treated amino acid–linked GPIs showing (M-H)2 ions of unconverted GPIs and GPIs lacking substituent at sn-2 position. (A–F) The major GPI(s)
that represent(s) the molecular ions are indicated. E, ethanolamine; P, phosphate; M4, Man4; Gn, GlcN; I, inositol; AG, acylglycerol; DAG, diacylglycerol;
S, serine. (G) The cleavage sites for the attachment of GPIs in P. falciparum MSPs.1569 Naik et al.
(z10%). The diacylglycerol moiety released on treatment
of GPI with HF contained predominantly C18:0 and C18:1
(two isomers), minor proportions of C14:0, C16:0, C18:2,
C20:0, and C22:0, and unidentified acids. As C18:1 and
C18:2 are present at sn-2 (see above), the remainders of the
above acids should be located at sn-1.
The mass spectra of the HPTLC-purified, amino acid–
linked GPIs (fraction I in Fig. 1 B, lane 4) containing one
amino acid after pronase digestion showed prominent mo-
lecular ions that are 87 mass units higher than those of free
GPIs (compare Fig. 2, E and F, with A), indicating that
these GPIs contain a Ser residue. GPIs with attached Asn
were also evident from (M2H)2 ions at m/z 2120.3,
2148.3, and 2176.3 in the mass spectrum (not shown) of
fraction II (Fig. 1 B, lane 4). This agrees with the predicted
amino acids in GPI-anchored surface proteins (13–15),
MSP-1, MSP-2, and MSP-4 (Fig. 2 G). Phospholipase A2
treatment caused reduction by 264.5 mass units in the m/z
of each of the molecular ions (Fig. 2 F), confirming the
presence of predominantly C18:1 acyl residues at sn-2.
The acyl substituents in the GPIs were also studied
by metabolic labeling with [3H]myristic, [3H]palmitic,
[3H]palmitoleic, [3H]stearic, [3H]oleic, [3H]linoleic, and
[3H]arachidonic acids. All except arachidonate were incor-
porated into the parasite GPIs (Fig. 3 and data not shown).
Treatment of the GPIs labeled with [3H]myristic and
[3H]palmitic acids with phospholipase A2 showed the pres-
ence of incorporated label only in the lyso-GPIs; the re-
leased fatty acids were not radioactive (Fig. 3). Upon treat-
ment with HF, the radioactivity was found to be present
on both the diacylglycerol and inositol carbohydrate moi-
eties (not shown). In the case of [3H]stearic acid, the radio-
activity was incorporated only to the diacylglycerol moiety
(not shown). These results agree with the presence of satu-
rated fatty acids at sn-1 and at C-2 of inositol, but not at sn-2,
established by mass spectrometry. The data also suggest
that the parasite does not incorporate saturated fatty acids as
unsaturated acids to the GPIs they synthesize or vice versa.
Treatment of [3H]palmitoleic, [3H]oleic, and [3H]linoleic
acid–labeled GPIs with phospholipase A2 released .90% of
the incorporated activity as free acid; the lyso-GPIs con-
tained negligible radioactivity (Fig. 3). Treatment with HF
showed that most of the incorporated radioactivity was on
the diacylglycerol moiety, and the inositol carbohydrate
moiety was not radioactive (not shown). These results
agree with the presence of unsaturated fatty acyl residues at
sn-2 as indicated by mass spectrometry of phospholipase
A2–treated GPIs. The incorporation of [3H]palmitoleic acid
to sn-2 is most likely after its conversion to cis-vaccenic
acid; this agrees with the presence of cis-vaccenic acid at
sn-2 of the GPIs (see above) and the ability of the parasite
to synthesize this acid (42).
Based on the above data, the structure shown in Fig. 4 is
proposed for P. falciparum GPIs.
TNF-a–inducing Activity of P. falciparum GPIs. Previ-
ous studies have shown that P. falciparum GPIs can induce
the expression of proinflammatory cytokines in macro-
phages (27–29). To determine if highly purified GPIs can in-
duce biologic activity, cultured murine macrophages were
incubated with 0.03–0.5 mM purified GPIs, and the
amount of TNF-a in the culture medium was measured.
Consistent with a previous finding (26), the purified para-
site GPIs induced TNF-a (30–450 pg/ml) in a dose-depen-
dent manner (not shown).
Analysis for the Natural Anti-GPI Antibody in Humans.
To examine whether people living in malaria endemic ar-
eas express naturally elicited anti-GPI antibodies, we ana-
lyzed sera from 300 adults in Western Kenya and 50 USA
adults not exposed to malaria. In ELISAs performed with a
coating of 2 ng/well of HPLC-purified, free GPIs, all Ken-
yan adult sera exhibited moderate to high levels of GPI-
specific antibodies, predominantly IgGs, whereas all USA
adults completely lacked anti-GPI antibodies (Fig. 5). The
anti-GPI antibody activity of Kenyan sera was dose depen-
dent and saturable (Fig. 5). There was no significant differ-
ence in levels of GPI-specific antibody reactivity between
Figure 3. P. falciparum GPIs contain predominantly C18:1 fatty acid at
sn-2. The parasites were metabolically labeled with various 3H–fatty acids.
Free GPIs were isolated, treated with bee venom phospholipase A2
(PLA2), and analyzed by HPTLC. 2, untreated GPIs; 1, phospholipase
A2–treated GPIs.
Figure 4. The proposed structures of P. falciparum GPIs. The fatty acids
and their molar proportions are indicated.1570 Structure and Antibody Response of P. falciparum GPIs
HPLC-purified free and amino acid–linked GPIs, indicat-
ing that the immunoreactivity is not due to contamination
by parasite proteins. More than 85% of Kenyan adult sera
also contained lower but significant levels of GPI-specific
IgM antibodies (Naik, R.S., unpublished results). The
erythrocyte membrane debris, saponin lysate, and ghosts
were nonreactive to the infected Kenyan sera (data not
shown).
When ELISA was performed using several commercially
available phospholipids, PIs from bovine liver and soybean
that lack acyl substituent on inositol, PGs, and CL, Ken-
yan adult sera showed a low level of activity: z5–15% of
that observed with P. falciparum GPIs. At all coating
concentrations tested (2–50 ng/well), these compounds
showed similar low levels of antibody reactivity. Prior in-
cubation of Kenyan sera with 2.5–20 ng/ml of PIs, PGs,
or CL, and then ELISA using plates coated with HPLC-
purified free GPIs showed in all cases z5–15% lower anti-
body binding activity, irrespective of the concentrations of
lipid used (Fig. 6). However, prior incubation with the
parasite GPIs inhibited binding by up to 75% in a dose-
dependent manner (Fig. 6). Together, these results suggest
that Kenyan adult sera have low levels of reactivity to
common acylated phosphoglycerols. This is not surprising
because of the polyclonal nature of GPI-specific antibod-
ies, which are expected to contain antibodies to the phos-
phoglycerol portion of GPIs that are common to this class
of molecules.
TLC immunoblotting of the HPTLC-purified GPIs
confirmed the specificity of the seroreactivity: adult Ken-
yan sera reacted with the GPIs, whereas control sera from
USA adults were nonreactive (Fig. 7). Furthermore, the
Kenyan adult sera were nonreactive to bovine liver and
soybean PIs that lack an acyl substituent on inositol, PGs,
and CL (Fig. 7, and data not shown); the apparent lack of
reactivity to these lipids on TLC plates could be due to a
low level of sensitivity. Furthermore, treatment of the GPIs
with HNO2 shifted the immunoreactivity to the position
of the PI moiety, suggesting that this portion of the mole-
cule is antigenic (Fig. 7).
The identity of the antigenic part of GPIs was further
confirmed by inhibition of seroreactivity to intact GPIs us-
ing carbohydrate and lipid moieties of GPIs isolated after
HNO2 fragmentation. The carbohydrate moiety inhibited
antibody binding by only z5% at a 10-fold higher concen-
tration compared with that of the coated, intact GPI. The
lipid moiety, at the same coating concentration as that of
intact GPIs, showed .70% antibody-binding activity, indi-
cating that the PI moiety is the antigenic structure. These
results suggest that acylated inositol is the major moiety that
recognizes the naturally elicited anti-GPI IgGs.
Anti-GPI Antibody Response and Acquired Resistance to Ma-
laria Pathogenesis. To determine whether the susceptibility
of young children in malaria endemic areas is related to the
absence of GPI-specific antibodies, sera taken every month
after birth for 4 yr from a cohort of 48 children were ana-
lyzed (8). The results were compared with those of sera
from 100 siblings (7–8 yr) and 50 nonpregnant mothers
(20–25 yr) (Fig. 8 A). Malaria parasitemia and clinical pa-
rameters (hemoglobin and fever) were followed every 2 wk
in this community-based cohort. Whereas a case-control
study design compares extremes, this nonbiased design de-
Figure 5. ELISA for naturally elicited anti-GPI antibodies in human
sera. The HPLC-purified, free GPIs were coated onto 96-well microtiter
plates either at the indicated amounts per well (A) or at 2 ng per well (B).
The wells were blocked with TBS-casein, and then incubated with hu-
man sera, 1:100 or serially diluted with TBS-casein, 0.05% Tween 20.
After washing the plates, the bound antibodies were detected with HRP-
conjugated goat anti–human IgG (H and L chains) using ABTS substrate.
d, Kenyan adult sera 1; m, Kenyan adult sera 2; j, Kenyan adult sera 3;
s, USA adult control serum.
Figure 6. Inhibition of anti-GPI antibody binding to GPIs by phos-
pholipids. The HPLC-purified, free GPIs were coated on to microtiter
plates (2 ng), blocked with TBS-casein, and overlaid with representative
Kenyan sera (1:200 diluted) incubated with the indicated phospholipids
and purified GPIs. The bound antibodies were measured by HRP-conju-
gated goat anti–human IgG (H and L chains) using ABTS substrate.
Shown are the data from a representative of 10 different sera analyzed.
Black bar, without inhibitor (Control); hatched bars, 2.5 ng; white bars, 5
ng; gray bars, 10 ng; stippled bars, 20 ng.1571 Naik et al.
termined if an association between anti-GPI antibodies and
malaria pathogenesis was detectable at a population level.
We carefully controlled for P. falciparum transmission, anti-
malaria drug treatment, and age. By sampling the same child
over 4 yr, we found that, within an individual, anti-GPI an-
tibody responses correlate with protection against malaria-
attributable hemoglobin loss and febrile illness (see below).
We performed ELISA on sera from each child on all
monthly samples and for siblings and adults at two time
points spaced 1–3 mo apart to determine the anti-GPI anti-
body level and the persistence of the antibody response.
For comparison and correlation analysis, results of four time
points (0.5, 1.5, 2.5, and 3.5 yr old), based on the sampling
scheme employed for the 7–8-yr-olds and the mothers,
were used for children (Fig. 8 A). The data show that
z50% of the children under 2 yr lacked anti-GPI antibod-
ies (negative responders, defined in the legend to Fig. 8),
z40% had short-lived antibody responses (lasted in the cir-
culation for only 1–3 mo, intermittent responders), and
only z10% had persistent (long-lived) antibody responses
(positive responders) (Fig. 8 A). In contrast, z75% of the
7–8-yr-old children and all adults exhibited a persistent
anti-GPI antibody response. The level of anti-GPI IgG in-
creased with increasing age from infancy to adulthood,
whereas mean hemoglobin density increased and fever
(temperature) decreased with age up to 7–8 yr of life (Fig. 8
B). Thus, the presence of long-lived, high levels of anti-
GPI antibodies in sera parallels the naturally acquired resis-
tance against malaria pathogenesis.
We found that anti-GPI antibody response, age, and par-
asite density were independently associated with hemoglo-
bin (P , 0.0147). Age influenced the anti-GPI antibody
responder category; however, it was not significant (P ,
0.0581), suggesting that the association between the anti-
body responder category (as defined in the legend to Fig. 8)
and hemoglobin was not just a reflection of age. For exam-
ple, using a general linear model, it was estimated that
6-mo-old children in the positive antibody responder cate-
gory had 2.37 g/dl of hemoglobin more than 6-mo-olds in
the intermittent responder category. Antibody responder
category and parasite density were independently associated
with temperature (P , 0.0012). 6-mo-olds in the negative
antibody responder category had an estimated temperature
0.718C higher than the individuals in the intermittent anti-
body responder category. Fig. 9 shows the associations be-
tween anti-GPI antibody responder category and malaria-
attributable pathology in children 0.5–3.5 yr old. In each
parasitemia category, febrile illness increased and hemoglo-
bin level decreased in children without antibodies or with
only short-lived antibodies; however, in children with per-
sistent antibodies, febrile illness was lower and hemoglobin
level was higher. These results strongly support the hy-
pothesis that circulating anti-GPI antibodies neutralize the
toxic effects of parasite GPIs.
Figure 7. HPTLC immunochromatogram of P. falciparum GPIs. The
HPTLC-purified, free GPIs (100 ng each) were chromatographed on
HPTLC plates, blocked with 1% BSA, and incubated for 2 h in 1:100-
diluted sera. The bound antibodies were detected with 125I-labeled goat
anti–human IgG (5 mCi/ml). Lanes 1 and 2, free and amino acid–linked
GPIs, respectively, treated with Kenyan adult sera; lanes 3 and 4, HNO2-
released lipid from free and amino acid–linked GPIs, respectively, treated
with Kenyan adult sera; lanes 5 and 6, free and amino acid–linked GPIs,
respectively, treated with control USA adult sera; lanes 7 and 8, PIs from
bovine liver and soybean, respectively; lane 9, PG; lane 10, CL, treated
with Kenyan adult sera. Shown are representatives of 10 Kenyan and
USA adult sera analyzed. Parasite lipids other than GPIs and their inter-
mediates, extracted with chloroform/methanol (2:1, vol/vol), and gly-
colipids from control erythrocytes were completely nonreactive to Ken-
yan sera (not shown).
Figure 8. Age-dependent anti-GPI antibody response in people living
in malaria endemic area. Sera from a cohort of children and adults were
analyzed by ELISA using HPLC-purified, free GPIs (see Fig. 5). An anti-
body level (OD) greater than the mean of USA adult control sera plus 2
SD was considered positive. (A) Percentage of individuals in the follow-
ing anti-GPI antibody responder categories: negative at both 1–3-mo-
spaced time points sampled, negative (white bars); positive at one time
point, intermittent (hatched bars); and positive at both time points, posi-
tive (black bars). n $ 40 in each age group between z0.5 and 3.5 yr, and
n 5 100 and 50 in the 7–8-yr and 20–25-yr age groups, respectively. A x2
test found that the antibody responder category was different among age
groups (P  ,  0.001). (B) Mean hemoglobin (g/dl, white bars), tem-
perature (229.58C, hatched bars), and anti-GPI antibody level
[log10(OD11)] (d) for the indicated age groups. Analysis of variance
found that the anti-GPI antibody level, hemoglobin, and temperature
were different among age groups (P , 0.0001).1572 Structure and Antibody Response of P. falciparum GPIs
Discussion
This paper reports two major findings. (a) The results
presented here establish for the first time that individuals
residing in malaria-endemic areas develop a P. falciparum–
specific anti-GPI antibody response, whereas people not
exposed to the malaria parasite do not have these antibod-
ies; in addition, anti-GPI antibody responses are correlated
with protection against malaria-related febrile illness and
hemoglobin loss. This agrees with the previous reports de-
scribing P. falciparum GPIs as pathogenicity factors based on
their ability to induce a spectrum of proinflammatory cy-
tokine responses and cause malaria symptoms. (b) Another
important finding is elucidation of complete structures of
the parasite GPIs by direct biochemical analysis and mass
spectrometry. Thus, our results identified two novel struc-
tural features of P. falciparum GPIs: the presence of palmi-
tate and myristate on C-2 of inositol, and the presence of
predominantly oleic and minor amounts of cis-vaccenic
acid and C18:2 at sn-2.
The purification of P. falciparum GPIs to homogeneity
was crucial for structural determination as well as to obtain
unambiguous evidence for biologic activity and establish
the presence and specificity of naturally elicited antibodies
in the sera of people living in malaria endemic areas. The
key steps employed for isolation and purification of GPIs
were: (a) growing of mycoplasma-free cultures to high lev-
els of parasitemia and enrichment of infected erythrocytes;
(b) metabolic labeling of GPIs and the use of human sera
containing anti-GPI antibodies to follow purification steps;
(c) use of sterile water and buffers and high quality organic
solvents to exclude external contamination; and (d) sili-
conizing glassware to avoid loss due to surface adsorption.
The mass spectrometry results presented here show that the
purified GPIs are homogeneous.
We determined the structures of P. falciparum GPIs by
subjecting the [3H]GlcN- and 3H–fatty acid-labeled GPIs
to various standard degradative procedures, including their
susceptibility to nitrous acid, HF, alkali, jack bean a-man-
nosidase, and GPI-specific phospholipase D, by determin-
ing fatty acid composition and finally by direct mass spec-
trometry. The results enabled us to propose the structures
shown in Fig. 4 for the parasite GPIs. The structure of the
core glycan is the same as determined previously (19, 20).
However, the acyl substituents are different from those re-
ported previously, based on radiolabeling, with palmitate at
both sn-1 and sn-2 and predominantly myristate on inositol
(21). As shown in Fig. 4, palmitate is the major acyl substit-
uent with minor proportions of myristate on inositol of the
parasite GPIs; GPIs with acylated inositol residues from
other sources reported to date contain only palmitate on
the inositol residue (12). The parasite GPIs contain unsat-
urated acyl substituents at sn-2 (major C18:1 and minor
C18:2) and predominantly C18:0 and a range of variable
size saturated acyl residues at sn-1. With respect to the na-
ture of the acyl residue at sn-2, the parasite GPIs resemble
the GPI of T. cruzi trypomastigote mucin that has a potent
cytokine-inducing property (30). Another unusual feature
of the parasite GPIs is the presence of cis-vaccenic acid at
sn-2.
The parasite GPIs differ significantly from those of hu-
mans with respect to both the acyl substituents and the car-
bohydrate moiety (12). The GPI moieties of human eryth-
rocyte proteins (the erythrocytes do not contain detectable
levels of free GPIs), CD59, and acetylcholine esterase con-
tain exclusively a C18 alkyl substituent at sn-1, C22:4 at
sn-2, and palmitate on inositol; the carbohydrate moieties
contain one or two extra phosphoethanolamine as well as
bGalNAc residues (12). The GPI of human spleen CD52
contains a diacylglycerol moiety and lacks GalNAc; how-
ever, this differs from the parasite GPIs with respect to the
type of fatty acid at sn-2 (C22:4, C22:5, and C22:6) and
contains phosphoethanolamine on the first mannose resi-
due (12). These structural differences may contribute to the
observed naturally elicited immunologic responses against
the parasite GPIs in humans.
Although Schofield et al. have shown that P. falciparum
GPIs can transduce signals to elicit inflammatory cytokine
Figure 9. Serum anti-GPI antibody response and resistance to malaria
in children 0.5–3.5 yr of age. A general linear model (GLM) was used to
investigate the correlation between anti-GPI antibody responder category
and temperature or hemoglobin level, while controlling for age and para-
site density. (A) Mean temperature (8C) for 0.5–3.5-yr-old negative
(white bars), intermittent (hatched bars), and positive (black bars) anti-
GPI antibody responder categories. (B) Mean hemoglobin (g/dl) for 0.5–
3.5-yr-old negative (white bars), intermittent (hatched bars), and positive
(black bars) anti-GPI antibody responder categories (see legend to Fig. 8).
The anti-GPI antibody responder category and parasite density were in-
dependently associated with hemoglobin (P , 0.0147 and P 5 0.0000,
respectively). The associations were independent of the nonsignificant as-
sociation between age and hemoglobin (P  5 0.0581). Antibody re-
sponder category and parasite density were independently associated with
temperature (P 5 0.0012 and 0.0001, respectively). Age was not found
significantly correlated with temperature (P . 0.0581).1573 Naik et al.
responses (27–29), there have been concerns as to whether
the observed activity was due to contamination (parasite,
erythrocytes, and/or mycoplasma origin [43]). These con-
cerns were based on the observations by some investigators
that aqueous buffer extracts of parasite cultures, presumed
to have extracted the parasite GPIs upon boiling, could not
elicit TNF-a. Thus, they have argued that the cytokine-
inducing property of P. falciparum was due to unknown
components. However, it should be noted that GPIs can
only be extracted with organic solvents. Because of this ex-
isting controversy, we tested TNF-a induction by the
highly purified parasite GPIs. The results presented in this
paper clearly show that the purified P. falciparum GPIs can
induce TNF-a in macrophages. This activity is consistent
with the recent finding by Almeida et al. that a highly pu-
rified GPI moiety of T. cruzi trypomastigote mucin in-
duces TNF-a (30) and confirms the previous finding by
Schofield et al. (26). Furthermore, studies by Almeida et al.
also show that C18:1 and/or C18:2 acyl substituent at sn-2
in the T. cruzi GPIs is critical for TNF-a–inducing activity
(30). As the P. falciparum GPI also contains C18:1 (major)
and C18:2 (minor) at sn-2, it is possible that these acyl sub-
stituents contribute to the toxic property of the parasite
GPIs.
In malaria endemic areas, younger children have the
highest risk of developing severe malaria, whereas older
children and adults rarely develop severe disease despite re-
peated exposure and significant parasitemia (23). People in
nonmalarious regions completely lack this resistance, sug-
gesting that the protection is due to a parasite-specific re-
sponse acquired through repeated infections. In the West-
ern Kenyan population studied here, we found that adults
have P. falciparum parasitemia .14% of the time, whereas
children ,4 yr old have parasitemia .60% of the time.
The density of parasitemia is lower in adults and, impor-
tantly, the level of parasitemia that can be tolerated without
causing febrile illness or anemia is higher in adults (Branch,
O.H., unpublished). As P. falciparum GPIs are pathogenic-
ity factors (26–29), the resistance of adults to malaria illness
may be related to a GPI-specific protective immunity.
All the Kenyan adult sera analyzed contained high levels
of GPI-specific IgGs, whereas all 50 USA adult sera com-
pletely lacked such antibodies. The antibody response was
highly specific to GPIs and their intermediates; other phos-
pholipids of the parasite showed only low levels of immu-
noreactivity. Several phospholipids, including PIs, PGs, and
CL, showed only 5–15% of the immunoreactivity exhib-
ited by the parasite GPIs, which appears to be due to the
polyclonal nature of the antibodies reacting with the com-
mon epitopes. Previously, several studies have reported the
presence of significant levels of antibodies that bind phos-
pholipids either directly or via binding of serum b2-glyco-
protein I (44). In those studies, lipids were coated with sev-
eral micrograms per well for ELISA. It is known that
proteins and antibodies can nonspecifically bind to lipids
when coated at high density. In contrast, our study used
0.5–2 ng/well of GPIs for ELISA and 100 ng for TLC im-
munoblots. Moreover, in previous studies, plates coated
with lipid antigens were incubated with sera diluted with
buffers without detergent. Under such conditions, we
found high levels of nonspecific activity. Thus, our study
clearly demonstrates that the identified IgGs are specific to
GPIs.
Our results also establish that the PI portion of the GPIs
contributes significantly to immunogenicity. The removal
of the sn-2 fatty acid from the GPIs did not affect antibody
reactivity (Vijaykumar, M., unpublished results). As treat-
ment with HF abolished immunoreactivity, it appears that
the acylated inositol phosphate is the immunogenic portion
of the molecule. This agrees with the previous finding that
antibodies raised against PIs can inhibit the induction of
TNF-a by P. falciparum extracts (45). These results are im-
portant in that if an sn-2 acyl substituent is indeed required
for cytokine-inducing activity, then it may be possible to
synthesize nontoxic molecules for therapeutic purposes.
The TNF-a–inducing activity of GPIs and the correla-
tion between the general resistance of adults in endemic ar-
eas to malaria pathogenesis and the presence of serum anti-
GPI antibody response suggest that the acquired immunity
is related significantly to the anti-GPI antibodies. This pre-
diction agrees with the lack of such an antibody response in
the majority of children ,4 yr old, the risk of children de-
veloping severe malaria, and the correlation between the
gradual acquisition of the antibody response in an age-
dependent manner (.80% of the 7–8-yr-olds having high
levels of serum antibody) and protection against malaria
with age. Thus, a direct correlation between anti-GPI anti-
bodies and malaria-related pathology could be observed in
young children.
High levels of antibodies against several other antigens
such as MSP-1, EBA-175, and circumsporozoite protein
are also present in adults, and therefore it may be argued
that the anti-GPI antibody response is not independent
from those antibodies. However, it is important to consider
that the anti-GPI antibody response is related to antidisease
immunity, whereas antibodies against parasite proteins
studied to date are involved in antiparasite immunity (con-
trolling parasite burden). Furthermore, whereas z80% of
children ,2 yr of age either lack or contain very low levels
of short-lived anti-GPI antibodies, these children can have
high levels of antibodies against MSP-1 and other proteins
(8, 9; and Branch, O.H., unpublished results). Although
there was a correlation between the levels of MSP-1 and
EBA-175 antibodies and protection against parasite density,
these antibody responses were not related to anti-GPI anti-
body response, protection against febrile illness, and hemo-
globin loss at any given parasite density.
Almost all malaria vaccine development efforts currently
being pursued use parasite proteins in a multicomponent
formulation, aimed at providing immunity against infection
(antiparasitic [5]). On the other hand, by blocking the toxic
effects of the parasite GPIs, a GPI-based vaccine might sig-
nificantly reduce malaria pathogenesis. The identification
of the PI moiety as the functional part of the molecules
should significantly simplify any approach towards the de-
velopment of antidisease measures.1574 Structure and Antibody Response of P. falciparum GPIs
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